Treeway

Executive Summary

Treeway is a clinical-stage biotechnology company founded in 2012 by two ALS patients, Bernard Muller and Robbert Jan Stuit, headquartered in Utrecht, Netherlands. The company is dedicated to developing therapies for amyotrophic lateral sclerosis (ALS), Alzheimer's disease, and other neurodegenerative conditions. Treeway has advanced its lead candidate into Phase 3 clinical trials, demonstrating significant progress from its patient-driven origins. The company's pipeline includes both RNA/gene therapy and small molecule approaches, reflecting a diversified strategy to address the complex pathology of neurodegenerative diseases. With a strong patient-centric mission and a potentially pivotal Phase 3 program, Treeway is positioned to make a meaningful impact in an area of high unmet medical need.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 topline data readout for lead candidate in ALS55% success
• Q1 2027Regulatory submission (NDA/BLA) for lead candidate if Phase 3 positive60% success
• Q4 2026Initiation of Phase 2 trial for Alzheimer's disease candidate70% success